{
  "version": 1,
  "groupId": "respiratory",
  "groupName": "Respiratory",
  "type": "bacterial",
  "updatedAt": "2025-01-11T00:00:00Z",
  "pathogens": [
    {
      "id": "strep_pneumoniae_respiratory",
      "name": "Streptococcus pneumoniae",
      "scientificName": "Streptococcus pneumoniae (Pneumococcus)",
      "definition": "Gram-positive diplococcus; leading cause of community-acquired pneumonia (CAP), meningitis, and invasive disease. S. pneumoniae is the most common bacterial cause of pneumonia worldwide.",
      "reservoir": {
        "primary": ["Human nasopharynx (asymptomatic carriage in 5-10% of adults, 20-40% of children)"],
        "secondary": ["Respiratory secretions of infected individuals"],
        "notes": "Humans are the only reservoir. Nasopharyngeal carriage is common, especially in young children. Carriage rates vary by age, season, and vaccination status."
      },
      "transmission": {
        "mode": "Respiratory droplets",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing)",
          "Direct contact with respiratory secretions",
          "Autoinoculation from nasopharynx to lungs"
        ],
        "notes": "Transmission is person-to-person via respiratory droplets. Pneumonia often follows viral upper respiratory infection."
      },
      "incubationPeriod": {
        "range": "1-3 days (variable)",
        "infectiousPeriod": "Infectious during symptomatic period (until effective antibiotic treatment)",
        "seasonality": "Winter and spring peaks (respiratory season)",
        "geographic": "Worldwide, with higher incidence in developing countries and among unvaccinated populations"
      },
      "riskFactors": [
        "Age extremes (elderly >65 years, children <5 years)",
        "Immunosuppression (HIV, cancer, transplant, corticosteroids)",
        "Chronic diseases (lung disease, heart disease, diabetes, liver disease, kidney disease)",
        "Asplenia or functional splenectomy",
        "Smoking and alcohol abuse",
        "Recent viral respiratory infection (influenza)",
        "Crowded living conditions"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Fever and chills (often sudden onset)",
          "Productive cough with purulent or rusty sputum",
          "Dyspnea (shortness of breath)",
          "Pleuritic chest pain",
          "Tachypnea and tachycardia",
          "Lobar consolidation on chest X-ray"
        ],
        "complications": [
          "Bacteremia and sepsis",
          "Meningitis",
          "Empyema (pleural effusion)",
          "Lung abscess",
          "Respiratory failure",
          "Death (5-7% mortality in hospitalized patients; higher in elderly)",
          "Acute respiratory distress syndrome (ARDS)"
        ],
        "caseDefinition": {
          "suspected": "Patient with fever + cough + dyspnea + lobar consolidation on chest imaging + risk factors",
          "confirmed": "Clinical illness + laboratory confirmation: positive sputum, blood, or pleural fluid culture for S. pneumoniae, OR positive urinary antigen test, OR PCR"
        }
      },
      "diagnosis": [
        "Sputum Gram stain and culture (Gram-positive diplococci)",
        "Blood culture (positive in 25-30% of cases)",
        "Urinary pneumococcal antigen test (rapid, detects most serotypes)",
        "Chest X-ray (lobar consolidation, often single lobe)",
        "PCR for S. pneumoniae",
        "Pleural fluid culture (if empyema present)"
      ],
      "treatment": "Penicillins (penicillin G, amoxicillin) or cephalosporins (ceftriaxone, cefotaxime) if susceptible. Macrolides (azithromycin) or fluoroquinolones (levofloxacin, moxifloxacin) for penicillin-resistant strains or atypical coverage. Vancomycin for highly resistant strains. Duration: 5-7 days for uncomplicated CAP.",
      "infectionControl": {
        "precautions": "Droplet Precautions (surgical mask) for first 24 hours of effective antibiotic treatment; then Standard Precautions",
        "screening": "Not routinely recommended",
        "cohorting": "Isolate cases during first 24 hours of treatment",
        "sourceControl": "Not applicable",
        "environmental": "Standard cleaning",
        "staffEducation": "Droplet precautions, recognition of severe pneumonia, vaccination importance, respiratory hygiene"
      },
      "outbreakTriggers": [
        "Clusters of ≥2-3 severe CAP cases in a facility (hospital, nursing home)",
        "Sudden spike in community pneumonia cases or closed group (military, prison)",
        "Emergence of vaccine-escape serotypes",
        "Increase above baseline rate"
      ],
      "reportingCommunication": [
        "Notify public health within 24 hours of suspected outbreak",
        "Contact tracing as indicated in closed settings",
        "Assess vaccination coverage in affected population",
        "Implement enhanced surveillance",
        "Update stakeholders and healthcare providers"
      ],
      "prevention": [
        "Vaccination: PCV13 (pneumococcal conjugate vaccine) for children and high-risk adults; PPSV23 (pneumococcal polysaccharide vaccine) for adults ≥65 years and high-risk groups",
        "Respiratory hygiene and cough etiquette",
        "Smoking cessation",
        "Influenza vaccination (reduces risk of secondary bacterial pneumonia)",
        "Early diagnosis and treatment",
        "Management of chronic diseases"
      ],
      "references": [
        {
          "label": "WHO - Pneumococcal Disease",
          "url": "https://www.who.int/news-room/fact-sheets/detail/pneumonia"
        },
        {
          "label": "CDC - Pneumococcal Disease",
          "url": "https://www.cdc.gov/pneumococcal/index.html"
        },
        {
          "label": "Saudi GDIPC - Respiratory Infections",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "mycobacterium_tuberculosis",
      "name": "Mycobacterium tuberculosis (TB)",
      "scientificName": "Mycobacterium tuberculosis",
      "definition": "Acid-fast bacillus causing chronic pulmonary or extrapulmonary tuberculosis. TB is a major global health threat, with potential for latent infection and reactivation disease.",
      "reservoir": {
        "primary": ["Humans with active pulmonary tuberculosis"],
        "secondary": ["Humans with latent TB infection (LTBI) - not infectious"],
        "notes": "Humans are the only reservoir. Approximately 25% of the world's population has latent TB infection. Only active pulmonary TB is infectious."
      },
      "transmission": {
        "mode": "Airborne (droplet nuclei)",
        "routes": [
          "Inhalation of airborne droplet nuclei (<5 microns) from coughing, sneezing, singing, or talking",
          "Close and prolonged contact with infectious person (household, healthcare, congregate settings)",
          "Poorly ventilated spaces increase transmission risk"
        ],
        "notes": "Transmission requires close and prolonged contact. Droplet nuclei can remain suspended in air for hours. Extrapulmonary TB (except laryngeal) is generally not infectious."
      },
      "incubationPeriod": {
        "range": "Weeks to months (typically 2-12 weeks for primary infection; years for reactivation)",
        "infectiousPeriod": "Infectious while pulmonary symptoms persist and until 2-3 weeks of effective anti-TB therapy (smear-negative and clinical improvement)",
        "seasonality": "Year-round, no specific seasonal pattern",
        "geographic": "Worldwide, with highest burden in sub-Saharan Africa, South Asia, and Southeast Asia"
      },
      "riskFactors": [
        "Immunosuppression (HIV/AIDS, TNF-alpha inhibitors, corticosteroids, transplant)",
        "Close and prolonged contact with active TB case",
        "Healthcare workers",
        "Congregate settings (prisons, homeless shelters, long-term care facilities)",
        "Malnutrition and poverty",
        "Diabetes, chronic kidney disease, silicosis",
        "Substance abuse (alcohol, injection drugs)",
        "Recent TB infection (<2 years)"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Chronic cough (>2-3 weeks)",
          "Hemoptysis (coughing up blood)",
          "Weight loss and anorexia",
          "Fever (often low-grade, night sweats)",
          "Fatigue and malaise",
          "Chest pain (if pleural involvement)",
          "Extrapulmonary manifestations (lymphadenitis, meningitis, bone/joint, genitourinary)"
        ],
        "complications": [
          "Miliary TB (disseminated disease)",
          "TB meningitis",
          "Respiratory failure",
          "Massive hemoptysis",
          "Drug-resistant TB (MDR-TB, XDR-TB)",
          "Death (untreated TB has 50% mortality)",
          "Post-TB lung disease (bronchiectasis, fibrosis)"
        ],
        "caseDefinition": {
          "suspected": "Patient with chronic cough + weight loss + fever + night sweats + risk factors (HIV, close contact, congregate setting) + chest X-ray abnormalities",
          "confirmed": "Laboratory confirmation: positive AFB smear, positive culture for M. tuberculosis, OR positive nucleic acid amplification test (NAAT/PCR)"
        }
      },
      "diagnosis": [
        "Sputum AFB (acid-fast bacilli) smear microscopy (3 specimens)",
        "Sputum culture for M. tuberculosis (gold standard, takes 2-8 weeks)",
        "Nucleic acid amplification test (NAAT/PCR) - rapid, same-day results",
        "Chest X-ray (upper lobe infiltrates, cavitation, lymphadenopathy)",
        "Tuberculin skin test (TST) or Interferon-Gamma Release Assay (IGRA) for latent TB",
        "Drug susceptibility testing (DST) for all culture-positive cases"
      ],
      "treatment": "Multi-drug anti-TB therapy: Intensive phase (2 months): Isoniazid + Rifampin + Pyrazinamide + Ethambutol (HRZE). Continuation phase (4 months): Isoniazid + Rifampin (HR). Total duration: 6 months for drug-susceptible pulmonary TB. MDR-TB requires 18-24 months with second-line drugs. Directly Observed Therapy (DOT) recommended.",
      "infectionControl": {
        "precautions": "Airborne Isolation (negative-pressure room, N95 respirator or PAPR for healthcare workers) until patient is non-infectious (3 consecutive negative AFB smears, clinical improvement, 2-3 weeks of effective therapy)",
        "screening": "Contact investigation: screen household and close contacts with TST or IGRA; chest X-ray if positive",
        "cohorting": "Isolate suspected/confirmed TB cases in airborne isolation rooms; cohort if multiple cases",
        "sourceControl": "Surgical mask on patient when outside isolation room; cough etiquette",
        "environmental": "Negative-pressure rooms with ≥12 air changes per hour (ACH); HEPA filtration; UV germicidal irradiation (UVGI)",
        "staffEducation": "Airborne precautions, N95 fit testing, recognition of TB symptoms, contact investigation protocols, DOT importance"
      },
      "outbreakTriggers": [
        "Any confirmed case in healthcare setting or closed community (prison, shelter, school)",
        "≥2 epidemiologically linked cases (same strain by genotyping)",
        "Cluster of cases above baseline rate",
        "MDR-TB or XDR-TB case"
      ],
      "reportingCommunication": [
        "Immediate public health notification within 24 hours of suspected or confirmed TB",
        "Contact tracing and screening of high-risk contacts",
        "Genotyping (RFLP, MIRU-VNTR, WGS) to confirm outbreak strain",
        "Coordinate with TB control program",
        "Implement enhanced infection control measures",
        "Update stakeholders and healthcare providers"
      ],
      "prevention": [
        "BCG vaccination (where indicated, primarily in high-burden countries)",
        "Respiratory protection (N95 masks) for healthcare workers and close contacts",
        "Early diagnosis and treatment of active TB",
        "Treatment of latent TB infection (LTBI) in high-risk individuals",
        "Infection control measures (airborne isolation, ventilation)",
        "Contact investigation and screening",
        "Public health education on TB symptoms and transmission"
      ],
      "references": [
        {
          "label": "WHO - Tuberculosis",
          "url": "https://www.who.int/news-room/fact-sheets/detail/tuberculosis"
        },
        {
          "label": "CDC - Tuberculosis",
          "url": "https://www.cdc.gov/tb/default.htm"
        },
        {
          "label": "Saudi GDIPC - TB Guidelines",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "bordetella_pertussis",
      "name": "Bordetella pertussis",
      "scientificName": "Bordetella pertussis",
      "definition": "Gram-negative coccobacillus causing pertussis (whooping cough). Pertussis is a highly contagious respiratory infection characterized by paroxysmal cough and inspiratory whoop.",
      "reservoir": {
        "primary": ["Humans (infected individuals and carriers)"],
        "secondary": ["Respiratory secretions"],
        "notes": "Humans are the only reservoir. Asymptomatic carriage is rare. Adolescents and adults with mild symptoms are often unrecognized sources of transmission to infants."
      },
      "transmission": {
        "mode": "Respiratory droplets",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing)",
          "Direct contact with respiratory secretions",
          "Highly contagious (attack rate 80-90% in susceptible household contacts)"
        ],
        "notes": "Transmission is highest during the catarrhal and early paroxysmal stages. Infants are at highest risk of severe disease and death."
      },
      "incubationPeriod": {
        "range": "7-10 days (range 4-21 days)",
        "infectiousPeriod": "Contagious from prodrome (catarrhal stage) through 3 weeks of paroxysmal cough, OR until 5 days after starting effective antibiotic therapy",
        "seasonality": "Summer and fall peaks in temperate climates",
        "geographic": "Worldwide, with resurgence in countries with high vaccination coverage due to waning immunity"
      },
      "riskFactors": [
        "Unvaccinated or incompletely vaccinated individuals",
        "Infants <6 months (too young to be fully vaccinated)",
        "Close contacts of cases (household, daycare, school)",
        "Waning immunity (adolescents and adults 5-10 years post-vaccination)",
        "Healthcare workers",
        "Pregnant women (risk of transmission to newborn)"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Catarrhal stage (1-2 weeks): mild cough, rhinorrhea, low-grade fever (resembles common cold)",
          "Paroxysmal stage (2-6 weeks): severe paroxysmal cough with inspiratory whoop, post-tussive vomiting, cyanosis",
          "Convalescent stage (weeks to months): gradual resolution of cough",
          "Infants: apnea, cyanosis, feeding difficulties (may not have whoop)"
        ],
        "complications": [
          "Pneumonia (secondary bacterial infection)",
          "Seizures and encephalopathy",
          "Apnea and respiratory failure (infants)",
          "Rib fractures from severe coughing",
          "Weight loss and dehydration",
          "Death (primarily in infants <6 months)",
          "Subconjunctival hemorrhage, epistaxis"
        ],
        "caseDefinition": {
          "suspected": "Clinical: cough illness lasting ≥2 weeks with paroxysms, whoop, or post-tussive vomiting, OR cough illness in infant <1 year with apnea",
          "confirmed": "Clinical illness + laboratory confirmation: positive PCR or culture for B. pertussis, OR epidemiologic link to confirmed case"
        }
      },
      "diagnosis": [
        "Nasopharyngeal swab or aspirate for PCR (most sensitive, especially in first 3 weeks)",
        "Nasopharyngeal culture (gold standard, but less sensitive and takes 5-7 days)",
        "Serology (IgG antibodies) - useful for late diagnosis or epidemiologic studies",
        "Chest X-ray (if pneumonia suspected)"
      ],
      "treatment": "Macrolides: azithromycin (5 days) or erythromycin (14 days) - first-line. Trimethoprim-sulfamethoxazole (alternative). Antibiotics most effective if started in catarrhal stage; reduce transmission but have limited effect on symptoms if started in paroxysmal stage. Supportive care: oxygen, hydration, nutrition.",
      "infectionControl": {
        "precautions": "Droplet Precautions (surgical mask) until 5 days after starting effective antibiotic therapy, OR 3 weeks after cough onset if no antibiotics",
        "screening": "Not routinely recommended; identify close contacts for prophylaxis",
        "cohorting": "Isolate cases; cohort if multiple cases",
        "sourceControl": "Exclude cases from group settings (school, daycare, work) until non-infectious",
        "environmental": "Standard cleaning",
        "staffEducation": "Droplet precautions, recognition of pertussis (paroxysmal cough, whoop), contact prophylaxis protocols, vaccination importance"
      },
      "outbreakTriggers": [
        "≥2 epidemiologically linked cases in institution (school, daycare, healthcare facility)",
        "Sudden local increase in pertussis cases",
        "Cluster above baseline rate",
        "Single case in high-risk setting (neonatal unit, maternity ward)"
      ],
      "reportingCommunication": [
        "Health authority alert within 24 hours of suspected or confirmed case",
        "Close contact assessment and chemoprophylaxis (macrolides for household and close contacts)",
        "Implement enhanced surveillance in affected settings",
        "Vaccination campaigns (Tdap booster) if outbreak in adolescents/adults",
        "Public health education on symptoms and prevention",
        "Update stakeholders (schools, daycares, healthcare facilities)"
      ],
      "prevention": [
        "Vaccination: DTaP (diphtheria-tetanus-acellular pertussis) for children at 2, 4, 6, 15-18 months, and 4-6 years; Tdap booster for adolescents (11-12 years) and adults",
        "Maternal Tdap vaccination during each pregnancy (27-36 weeks) - protects newborns",
        "Chemoprophylaxis for close contacts (macrolides)",
        "Public and healthcare worker education on pertussis symptoms",
        "Respiratory etiquette and cough hygiene",
        "Prompt medical attention for prolonged cough",
        "Cocooning strategy: vaccinate household contacts of newborns"
      ],
      "references": [
        {
          "label": "WHO - Pertussis",
          "url": "https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/pertussis"
        },
        {
          "label": "CDC - Pertussis (Whooping Cough)",
          "url": "https://www.cdc.gov/pertussis/index.html"
        },
        {
          "label": "Saudi GDIPC - Respiratory Infections",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "corynebacterium_diphtheriae",
      "name": "Corynebacterium diphtheriae",
      "scientificName": "Corynebacterium diphtheriae",
      "definition": "Gram-positive rod causing diphtheria, a toxin-mediated disease characterized by pseudomembrane formation in the throat and systemic toxicity. Diphtheria is vaccine-preventable but remains a threat in unvaccinated populations.",
      "reservoir": {
        "primary": ["Human throat and nasopharynx (carriers and infected individuals)"],
        "secondary": ["Skin lesions (cutaneous diphtheria)"],
        "notes": "Humans are the only reservoir. Asymptomatic carriers can transmit the disease. Cutaneous diphtheria is less severe but can be a source of transmission."
      },
      "transmission": {
        "mode": "Respiratory droplets and direct contact",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing)",
          "Direct contact with respiratory secretions",
          "Direct contact with skin lesions (cutaneous diphtheria)",
          "Fomites (contaminated objects)"
        ],
        "notes": "Transmission is person-to-person. Crowded settings and poor hygiene increase transmission risk."
      },
      "incubationPeriod": {
        "range": "2-5 days (range 1-10 days)",
        "infectiousPeriod": "Infectious until bacteria and toxin are eradicated (typically 2 weeks without treatment; <4 days with antibiotics)",
        "seasonality": "Fall and winter peaks in temperate climates",
        "geographic": "Worldwide, with highest incidence in areas with low vaccination coverage (sub-Saharan Africa, South Asia)"
      },
      "riskFactors": [
        "Unvaccinated or incompletely vaccinated individuals",
        "Crowded living conditions (refugee camps, prisons, homeless shelters)",
        "Poor hygiene and sanitation",
        "Travel to endemic areas",
        "Close contact with cases or carriers",
        "Immunocompromised individuals",
        "Alcoholism and substance abuse"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Sore throat and difficulty swallowing",
          "Low-grade fever and malaise",
          "Adherent gray-white pseudomembrane on tonsils, pharynx, or larynx (hallmark)",
          "Bull neck appearance (cervical lymphadenopathy and edema)",
          "Hoarseness and stridor (if laryngeal involvement)",
          "Cutaneous diphtheria: non-healing ulcers with gray membrane"
        ],
        "complications": [
          "Myocarditis (cardiac toxicity) - leading cause of death",
          "Neuritis (cranial nerve palsies, peripheral neuropathy)",
          "Nephritis (kidney damage)",
          "Airway obstruction (pseudomembrane)",
          "Respiratory failure",
          "Death (5-10% mortality with treatment; up to 50% without treatment)",
          "Septic shock"
        ],
        "caseDefinition": {
          "suspected": "Clinical: sore throat + adherent pseudomembrane on tonsils/pharynx + bull neck appearance, OR cutaneous ulcer with gray membrane + epidemiologic link",
          "confirmed": "Clinical illness + laboratory confirmation: positive culture for toxigenic C. diphtheriae, OR positive PCR with toxin gene detection"
        }
      },
      "diagnosis": [
        "Throat or nasopharyngeal swab for culture (Loeffler medium, tellurite agar)",
        "PCR for C. diphtheriae and toxin gene (tox)",
        "Toxin detection (Elek test or PCR)",
        "Gram stain (Gram-positive rods with metachromatic granules)",
        "ECG (to detect myocarditis)",
        "Throat examination (visualize pseudomembrane - do not remove forcibly)"
      ],
      "treatment": "Diphtheria antitoxin (DAT) - CRITICAL, must be given as soon as possible (neutralizes circulating toxin, does not affect toxin already bound to tissues). Antibiotics: penicillin G or erythromycin (14 days) - eradicates bacteria and stops toxin production. Supportive care: airway management, cardiac monitoring, bed rest. Isolation until 2 consecutive negative cultures (24 hours apart, after completing antibiotics).",
      "infectionControl": {
        "precautions": "Droplet and Contact Precautions until 2 consecutive negative cultures (24 hours apart, after completing antibiotics)",
        "screening": "Identify and screen close contacts; obtain throat cultures",
        "cohorting": "Strict isolation of cases; cohort if multiple cases",
        "sourceControl": "Chemoprophylaxis of close contacts (erythromycin or penicillin for 7-10 days) + booster vaccination",
        "environmental": "Thorough cleaning and disinfection of contaminated surfaces and fomites",
        "staffEducation": "Droplet and contact precautions, recognition of diphtheria (pseudomembrane, bull neck), antitoxin administration urgency, contact prophylaxis protocols"
      },
      "outbreakTriggers": [
        "Any single confirmed case (diphtheria is a public health emergency)",
        "≥2 presumptive cases in a group or community",
        "Cluster of sore throat cases with pseudomembrane",
        "Case in unvaccinated or under-vaccinated population"
      ],
      "reportingCommunication": [
        "Immediate health authority notification within 24 hours (or sooner) of suspected case",
        "Contact tracing and screening of all close contacts",
        "Mass chemoprophylaxis and vaccination campaigns in affected communities",
        "Coordinate with public health for antitoxin procurement (often requires national/international coordination)",
        "Public health alerts and media communication",
        "Update stakeholders (schools, healthcare facilities, community leaders)"
      ],
      "prevention": [
        "Vaccination: DTaP (diphtheria-tetanus-acellular pertussis) for children at 2, 4, 6, 15-18 months, and 4-6 years; Td or Tdap booster every 10 years for adults",
        "Catch-up vaccination for unvaccinated or incompletely vaccinated individuals",
        "Chemoprophylaxis and booster vaccination for close contacts",
        "Hygiene and sanitation improvements",
        "Reporting of sore throat outbreaks with pseudomembrane",
        "Public health education on diphtheria symptoms and vaccination importance",
        "Surveillance and outbreak response preparedness"
      ],
      "references": [
        {
          "label": "WHO - Diphtheria",
          "url": "https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/diphtheria"
        },
        {
          "label": "CDC - Diphtheria",
          "url": "https://www.cdc.gov/diphtheria/index.html"
        },
        {
          "label": "Saudi GDIPC - Vaccine-Preventable Diseases",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "chlamydia_psittaci",
      "name": "Chlamydia psittaci",
      "scientificName": "Chlamydia psittaci",
      "definition": "Obligate intracellular bacteria causing psittacosis (parrot fever), a zoonotic atypical pneumonia. C. psittaci is transmitted from birds to humans and can cause severe respiratory illness.",
      "reservoir": {
        "primary": ["Birds (especially parrots, parakeets, cockatiels, pigeons, poultry)"],
        "secondary": ["Contaminated bird droppings, feathers, and respiratory secretions"],
        "notes": "Birds are the primary reservoir. Infected birds may be asymptomatic or show signs of illness (ruffled feathers, lethargy, diarrhea). Human-to-human transmission is extremely rare."
      },
      "transmission": {
        "mode": "Inhalation of aerosolized particles",
        "routes": [
          "Inhalation of aerosolized dried bird droppings, respiratory secretions, or feathers",
          "Direct contact with infected birds (pet shops, aviaries, poultry farms)",
          "Handling infected bird carcasses or tissues",
          "Rarely: human-to-human transmission (extremely rare, only a few documented cases)"
        ],
        "notes": "Transmission occurs through inhalation of contaminated aerosols. Brief exposure can be sufficient for infection. Occupational exposure (pet shop workers, veterinarians, poultry workers) increases risk."
      },
      "incubationPeriod": {
        "range": "5-14 days (range 4-19 days)",
        "infectiousPeriod": "Infectious period for birds is prolonged (weeks to months); human-to-human transmission is extremely rare",
        "seasonality": "Year-round, no specific seasonal pattern",
        "geographic": "Worldwide, wherever birds are kept or handled"
      },
      "riskFactors": [
        "Bird exposure (pet birds, poultry, wild birds)",
        "Occupational exposure (pet shop workers, veterinarians, poultry workers, bird breeders)",
        "Elderly and immunocompromised individuals (higher risk of severe disease)",
        "Cleaning bird cages or handling bird droppings without protection",
        "Visiting aviaries or bird shows"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Atypical pneumonia (fever, dry cough, dyspnea)",
          "Severe headache (often prominent)",
          "Myalgia and malaise",
          "Fever and chills",
          "Sometimes hepatosplenomegaly (enlarged liver and spleen)",
          "Relative bradycardia (pulse-temperature dissociation)",
          "Gastrointestinal symptoms (nausea, vomiting, diarrhea)"
        ],
        "complications": [
          "Severe pneumonia and respiratory failure",
          "Endocarditis (rare but serious)",
          "Myocarditis and pericarditis",
          "Hepatitis",
          "Encephalitis and meningitis",
          "Disseminated intravascular coagulation (DIC)",
          "Death (1% mortality with treatment; higher without treatment)"
        ],
        "caseDefinition": {
          "suspected": "Clinical: atypical pneumonia + severe headache + bird exposure history (within 2 weeks)",
          "confirmed": "Clinical illness + laboratory confirmation: positive serology (4-fold rise in antibody titer or single high titer), OR positive PCR from respiratory specimens"
        }
      },
      "diagnosis": [
        "Serology (complement fixation, microimmunofluorescence) - 4-fold rise in titer or single high titer",
        "PCR from respiratory specimens (sputum, bronchoalveolar lavage) - specialized labs",
        "Chest X-ray (patchy infiltrates, often lower lobes)",
        "Culture (rarely performed due to biosafety concerns - requires BSL-3 lab)",
        "History of bird exposure is key diagnostic clue"
      ],
      "treatment": "Doxycycline (100 mg twice daily for 10-14 days) - first-line. Macrolides (azithromycin, erythromycin) - alternative. Fluoroquinolones (levofloxacin, moxifloxacin) - alternative. Treatment should be started empirically if psittacosis is suspected, without waiting for laboratory confirmation.",
      "infectionControl": {
        "precautions": "Standard Precautions (human-to-human transmission is extremely rare)",
        "screening": "Not routinely recommended; identify bird exposure sources",
        "cohorting": "Not needed",
        "sourceControl": "Identify and eliminate infected bird sources; quarantine and treat infected birds; proper disposal of bird carcasses",
        "environmental": "Respiratory protection (N95 mask) during bird handling, cage cleaning, or necropsy; wet cleaning to avoid aerosolization; disinfection of contaminated areas",
        "staffEducation": "Recognition of psittacosis (atypical pneumonia + bird exposure), biosafety for bird handlers, reporting requirements"
      },
      "outbreakTriggers": [
        "≥2 cases epidemiologically linked to a shared bird exposure source (pet shop, aviary, poultry farm)",
        "Cluster of atypical pneumonia cases with bird exposure",
        "Single case with severe illness and confirmed bird source"
      ],
      "reportingCommunication": [
        "Health authority reporting within 24 hours of suspected or confirmed case",
        "Coordinated investigation with veterinary and public health authorities",
        "Identify and investigate bird exposure sources",
        "Quarantine and testing of implicated birds",
        "Public health alerts to at-risk populations (bird owners, pet shop workers)",
        "Update stakeholders (veterinary services, pet shops, poultry farms)"
      ],
      "prevention": [
        "Educate bird handlers and breeders on psittacosis risks",
        "Biosafety measures for at-risk workers (respiratory protection, hand hygiene)",
        "Quarantine and testing of newly acquired birds (especially imported birds)",
        "Proper ventilation in bird housing areas",
        "Wet cleaning of bird cages to avoid aerosolization",
        "Prompt veterinary care for sick birds",
        "Avoid mouth-to-beak contact with birds",
        "Reporting of sick birds to veterinary authorities"
      ],
      "references": [
        {
          "label": "CDC - Psittacosis",
          "url": "https://www.cdc.gov/psittacosis/index.html"
        },
        {
          "label": "WHO - Zoonoses",
          "url": "https://www.who.int/health-topics/zoonoses"
        },
        {
          "label": "Saudi GDIPC - Zoonotic Infections",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "mycoplasma_pneumoniae",
      "name": "Mycoplasma pneumoniae",
      "scientificName": "Mycoplasma pneumoniae",
      "definition": "Wall-less, small bacteria causing atypical pneumonia (walking pneumonia), especially in children and adolescents. M. pneumoniae is a common cause of community-acquired pneumonia in school-aged children and young adults.",
      "reservoir": {
        "primary": ["Human respiratory tract"],
        "secondary": ["Respiratory secretions"],
        "notes": "Humans are the only reservoir. Asymptomatic carriage is uncommon. Transmission occurs through close contact in households, schools, and military barracks."
      },
      "transmission": {
        "mode": "Respiratory droplets and close contact",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing)",
          "Direct contact with respiratory secretions",
          "Prolonged close contact (household, school, dormitory)"
        ],
        "notes": "Transmission is slow and requires prolonged close contact. Incubation period is long (1-4 weeks), leading to gradual spread within communities."
      },
      "incubationPeriod": {
        "range": "1-4 weeks (typically 2-3 weeks)",
        "infectiousPeriod": "Infectious while symptomatic (can shed bacteria for weeks to months after symptom onset)",
        "seasonality": "Year-round, with peaks in late summer and fall; epidemic cycles every 3-7 years",
        "geographic": "Worldwide, with higher incidence in temperate climates"
      },
      "riskFactors": [
        "School-aged children and adolescents (5-20 years)",
        "Military recruits and boarding school students",
        "Close contact settings (households, schools, dormitories)",
        "Immunocompromised individuals (higher risk of severe disease)",
        "Sickle cell disease (risk of acute chest syndrome)"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Atypical pneumonia: gradual onset of dry, persistent cough",
          "Fever (usually low-grade) and malaise",
          "Headache and myalgia",
          "Sore throat and hoarseness",
          "Minimal sputum production",
          "Chest X-ray findings out of proportion to physical exam (walking pneumonia)",
          "Extrapulmonary manifestations: rash, hemolytic anemia, arthritis, encephalitis"
        ],
        "complications": [
          "Severe pneumonia (rare)",
          "Pleural effusion",
          "Hemolytic anemia (cold agglutinin disease)",
          "Encephalitis and meningitis",
          "Guillain-Barré syndrome",
          "Stevens-Johnson syndrome (rare)",
          "Myocarditis and pericarditis",
          "Acute chest syndrome (in sickle cell disease patients)"
        ],
        "caseDefinition": {
          "suspected": "Clinical: atypical pneumonia (dry cough, fever, malaise) in school-aged child or young adult + chest X-ray infiltrates + epidemiologic link (school, household cluster)",
          "confirmed": "Clinical illness + laboratory confirmation: positive PCR from respiratory specimen, OR 4-fold rise in serology (IgM or IgG)"
        }
      },
      "diagnosis": [
        "PCR from respiratory specimens (throat swab, sputum, nasopharyngeal swab) - most sensitive and specific",
        "Serology (IgM and IgG antibodies) - IgM appears 1-2 weeks after symptom onset",
        "Chest X-ray (patchy infiltrates, often bilateral lower lobes)",
        "Culture (rarely performed, requires specialized media and takes 2-3 weeks)",
        "Cold agglutinins (non-specific, positive in 50% of cases)"
      ],
      "treatment": "Macrolides (azithromycin, clarithromycin, erythromycin) - first-line. Tetracyclines (doxycycline) - alternative for older children and adults. Fluoroquinolones (levofloxacin, moxifloxacin) - alternative. Duration: 5-10 days. Note: Beta-lactams (penicillins, cephalosporins) are ineffective (M. pneumoniae lacks cell wall).",
      "infectionControl": {
        "precautions": "Droplet Precautions (surgical mask) for hospitalized patients; Standard Precautions for outpatients",
        "screening": "Not routinely recommended",
        "cohorting": "Cohort cases if multiple hospitalized patients",
        "sourceControl": "Exclude symptomatic cases from close-contact settings (school, daycare) until clinically improved",
        "environmental": "Standard cleaning",
        "staffEducation": "Droplet precautions, recognition of atypical pneumonia, appropriate antibiotic selection (avoid beta-lactams)"
      },
      "outbreakTriggers": [
        "≥2 epidemiologically linked cases in institutional or closed settings (school, military barracks, boarding school)",
        "Cluster of atypical pneumonia cases above baseline rate",
        "Sudden increase in community pneumonia cases in children/adolescents"
      ],
      "reportingCommunication": [
        "Timely health authority notification within 24 hours of suspected outbreak",
        "Enhanced surveillance in affected settings (schools, military)",
        "Public health education on symptoms and prevention",
        "Coordinate with schools and institutions for outbreak control",
        "Update stakeholders and healthcare providers"
      ],
      "prevention": [
        "Public and childcare awareness of atypical pneumonia symptoms",
        "Respiratory hygiene and cough etiquette",
        "Prompt medical attention for persistent cough",
        "Exclude symptomatic individuals from close-contact settings",
        "Hand hygiene",
        "No vaccine currently available"
      ],
      "references": [
        {
          "label": "CDC - Mycoplasma pneumoniae Infection",
          "url": "https://www.cdc.gov/pneumonia/atypical/mycoplasma.html"
        },
        {
          "label": "WHO - Community-Acquired Pneumonia",
          "url": "https://www.who.int/news-room/fact-sheets/detail/pneumonia"
        },
        {
          "label": "Saudi GDIPC - Respiratory Infections",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "haemophilus_influenzae_respiratory",
      "name": "Haemophilus influenzae (type b and nontypeable)",
      "scientificName": "Haemophilus influenzae",
      "definition": "Gram-negative coccobacilli causing noninvasive (bronchitis, otitis media, sinusitis) and invasive (pneumonia, meningitis, epiglottitis, sepsis) respiratory infections. Type b (Hib) causes most invasive disease; nontypeable strains cause mucosal infections.",
      "reservoir": {
        "primary": ["Human nasopharynx (asymptomatic carriage in 2-5% of children, <1% of adults)"],
        "secondary": ["Respiratory secretions"],
        "notes": "Humans are the only reservoir. Carriage rates have dramatically decreased since introduction of Hib vaccine. Nontypeable H. influenzae (NTHi) is more common in adults with chronic lung disease."
      },
      "transmission": {
        "mode": "Respiratory droplets",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing)",
          "Direct contact with respiratory secretions",
          "Close contact with carriers or cases (household, daycare)"
        ],
        "notes": "Transmission requires close contact. Invasive Hib disease is rare in vaccinated populations. NTHi causes exacerbations of chronic obstructive pulmonary disease (COPD)."
      },
      "incubationPeriod": {
        "range": "Type b: 2-4 days (variable); NTHi: variable",
        "infectiousPeriod": "Contagious while symptomatic (until 24-48 hours after effective antibiotic treatment for invasive disease)",
        "seasonality": "Fall and winter peaks (respiratory season)",
        "geographic": "Worldwide, with highest incidence in unvaccinated populations and developing countries"
      },
      "riskFactors": [
        "Unvaccinated children <5 years (especially <2 years) for Hib",
        "Elderly and immunocompromised for NTHi",
        "Chronic lung disease (COPD, bronchiectasis) for NTHi",
        "Asplenia or functional splenectomy",
        "Cochlear implants or CSF leaks",
        "Smoking",
        "Crowded living conditions"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Community-acquired pneumonia (fever, cough, dyspnea, chest pain)",
          "Epiglottitis (stridor, drooling, tripod position) - medical emergency",
          "Meningitis (fever, headache, stiff neck)",
          "Sepsis and bacteremia",
          "Bronchitis and exacerbations of COPD (NTHi)",
          "Otitis media and sinusitis (NTHi)"
        ],
        "complications": [
          "Respiratory failure",
          "Empyema (pleural effusion)",
          "Meningitis and neurological sequelae",
          "Septic shock",
          "Airway obstruction (epiglottitis)",
          "Death (3-6% mortality for invasive disease with treatment)",
          "Hearing loss (if meningitis)"
        ],
        "caseDefinition": {
          "suspected": "Clinical: CAP, epiglottitis, meningitis, or sepsis + risk factors (unvaccinated child, elderly, chronic lung disease)",
          "confirmed": "Clinical illness + laboratory confirmation: positive culture from blood, CSF, pleural fluid, or other sterile site for H. influenzae, OR positive PCR with serotyping (if type b)"
        }
      },
      "diagnosis": [
        "Culture from blood, CSF, pleural fluid, or other sterile sites (chocolate agar with CO2)",
        "Gram stain (Gram-negative coccobacilli)",
        "PCR for H. influenzae",
        "Serotyping to confirm type b (capsular antigen detection)",
        "Chest X-ray (lobar or patchy infiltrates)",
        "Lateral neck X-ray (thumb sign for epiglottitis - but do not delay treatment)"
      ],
      "treatment": "Third-generation cephalosporins (ceftriaxone or cefotaxime) - first-line empiric (due to ampicillin resistance in 30-50% of strains). Fluoroquinolones (levofloxacin, moxifloxacin) - alternative for adults. Duration: 7-10 days for pneumonia; 10-14 days for meningitis. Epiglottitis requires airway management (intubation) + antibiotics.",
      "infectionControl": {
        "precautions": "Droplet Precautions (surgical mask) until 24 hours after effective antibiotic treatment for invasive disease",
        "screening": "Not routinely recommended; identify close contacts for prophylaxis (if invasive Hib)",
        "cohorting": "Isolate cases during first 24 hours of treatment",
        "sourceControl": "Chemoprophylaxis for close contacts (rifampin) if household includes unvaccinated or incompletely vaccinated children <4 years (for invasive Hib only)",
        "environmental": "Standard cleaning",
        "staffEducation": "Droplet precautions, recognition of invasive H. influenzae disease (epiglottitis, meningitis), vaccination importance, contact prophylaxis protocols"
      },
      "outbreakTriggers": [
        "≥2 linked invasive cases (especially Hib)",
        "Spike over baseline rate",
        "Single invasive Hib case in vaccinated population (suggests vaccine failure or waning immunity)",
        "Cluster of pneumonia cases in elderly or COPD patients (NTHi)"
      ],
      "reportingCommunication": [
        "Immediate health authority alert within 24 hours of invasive Hib case",
        "Contact monitoring and prophylaxis (if Hib)",
        "Assess vaccination coverage",
        "Enhanced surveillance in affected settings",
        "Update stakeholders and healthcare providers"
      ],
      "prevention": [
        "Hib vaccination: primary series at 2, 4, 6 months + booster at 12-15 months (part of routine childhood immunization)",
        "Catch-up vaccination for unvaccinated or incompletely vaccinated children",
        "Chemoprophylaxis for close contacts (rifampin) if invasive Hib",
        "Respiratory hygiene and cough etiquette",
        "Smoking cessation",
        "Prompt treatment of respiratory infections in COPD patients"
      ],
      "references": [
        {
          "label": "CDC - Haemophilus influenzae Disease",
          "url": "https://www.cdc.gov/hi-disease/index.html"
        },
        {
          "label": "WHO - Haemophilus influenzae type b (Hib)",
          "url": "https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/haemophilus-influenzae-type-b"
        },
        {
          "label": "Saudi GDIPC - Respiratory Infections",
          "url": "https://gdipc.org"
        }
      ]
    },
    {
      "id": "strep_pyogenes_respiratory",
      "name": "Streptococcus pyogenes (Group A Streptococcus)",
      "scientificName": "Streptococcus pyogenes (Group A Streptococcus, GAS)",
      "definition": "Gram-positive cocci causing pharyngitis (strep throat), scarlet fever, pneumonia, toxic shock syndrome, and necrotizing pneumonia. GAS is a common cause of bacterial pharyngitis and can cause severe invasive disease.",
      "reservoir": {
        "primary": ["Human throat and skin"],
        "secondary": ["Respiratory secretions", "Skin lesions"],
        "notes": "Humans are the only reservoir. Asymptomatic pharyngeal carriage occurs in 5-15% of school-aged children. Skin colonization is common in tropical climates."
      },
      "transmission": {
        "mode": "Respiratory droplets and direct contact",
        "routes": [
          "Respiratory droplets from close contact (coughing, sneezing, talking)",
          "Direct contact with respiratory secretions",
          "Direct contact with skin lesions (impetigo, cellulitis)",
          "Rarely: foodborne transmission (contaminated food)"
        ],
        "notes": "Transmission is person-to-person. Pharyngitis is highly contagious, especially in crowded settings (schools, military barracks). Invasive GAS disease can follow viral respiratory infections (influenza, varicella)."
      },
      "incubationPeriod": {
        "range": "1-3 days (range 12 hours to 5 days)",
        "infectiousPeriod": "Contagious from onset of symptoms until 24 hours after starting effective antibiotic treatment (untreated: 2-3 weeks)",
        "seasonality": "Winter and spring peaks for pharyngitis; summer for skin infections",
        "geographic": "Worldwide, with higher incidence in temperate climates for pharyngitis and tropical climates for skin infections"
      },
      "riskFactors": [
        "Age 5-15 years (pharyngitis)",
        "Close contact settings (schools, military barracks, households)",
        "Recent viral respiratory infection (influenza, varicella)",
        "Immunocompromised individuals",
        "Chronic diseases (diabetes, cancer, HIV)",
        "Skin trauma or wounds",
        "Injection drug use (invasive GAS)"
      ],
      "clinicalFeatures": {
        "symptoms": [
          "Pharyngitis: sore throat, fever, tonsillar exudates, tender cervical lymphadenopathy, absence of cough",
          "Scarlet fever: pharyngitis + sandpaper-like rash + strawberry tongue",
          "Pneumonia: fever, cough, dyspnea, pleuritic chest pain (often post-influenza)",
          "Necrotizing pneumonia: severe pneumonia with tissue necrosis and empyema",
          "Toxic shock syndrome: fever, hypotension, multi-organ failure, diffuse erythematous rash",
          "Invasive GAS: bacteremia, sepsis, necrotizing fasciitis"
        ],
        "complications": [
          "Acute rheumatic fever (ARF) - follows untreated pharyngitis",
          "Post-streptococcal glomerulonephritis (PSGN)",
          "Peritonsillar abscess (quinsy)",
          "Necrotizing pneumonia with empyema",
          "Streptococcal toxic shock syndrome (STSS) - high mortality (30-50%)",
          "Necrotizing fasciitis",
          "Death (mortality varies: <1% for pharyngitis; 30-50% for STSS/necrotizing fasciitis)"
        ],
        "caseDefinition": {
          "suspected": "Clinical: pharyngitis (sore throat, fever, tonsillar exudates, no cough) OR pneumonia post-influenza OR toxic shock syndrome + epidemiologic link",
          "confirmed": "Clinical illness + laboratory confirmation: positive throat culture or rapid antigen detection test (RADT) for pharyngitis, OR positive culture from blood or sterile site for invasive disease"
        }
      },
      "diagnosis": [
        "Throat culture (gold standard for pharyngitis) - blood agar with beta-hemolysis",
        "Rapid antigen detection test (RADT) - quick but less sensitive than culture",
        "Blood culture (for invasive disease)",
        "Culture from sterile sites (pleural fluid, CSF, tissue)",
        "Chest X-ray (for pneumonia - lobar consolidation, empyema)",
        "Anti-streptolysin O (ASO) titer (for post-streptococcal sequelae)"
      ],
      "treatment": "Penicillins (penicillin V, amoxicillin) - first-line for pharyngitis (10 days). Cephalosporins (cephalexin) - alternative. Macrolides (azithromycin, erythromycin) - if penicillin allergy. For invasive disease/necrotizing pneumonia: IV penicillin G + clindamycin (clindamycin inhibits toxin production). IVIG for toxic shock syndrome. Surgical debridement for necrotizing fasciitis.",
      "infectionControl": {
        "precautions": "Droplet Precautions (surgical mask) until 24 hours after effective antibiotic treatment",
        "screening": "Not routinely recommended; screen close contacts if outbreak",
        "cohorting": "Isolate cases during first 24 hours of treatment",
        "sourceControl": "Exclude cases from school, daycare, or work until 24 hours after starting antibiotics",
        "environmental": "Standard cleaning; disinfection of contaminated surfaces",
        "staffEducation": "Droplet precautions, recognition of invasive GAS (necrotizing fasciitis, STSS), importance of early antibiotic treatment, post-streptococcal sequelae prevention"
      },
      "outbreakTriggers": [
        "≥2 epidemiologically linked cases of pharyngitis or scarlet fever in institution (school, military, nursing home)",
        "Cluster of invasive GAS cases (≥2 cases in same community within short time period)",
        "Sudden increase in pharyngitis or scarlet fever cases above baseline",
        "Post-influenza cluster of severe pneumonia or invasive GAS"
      ],
      "reportingCommunication": [
        "Timely health authority notification within 24 hours of suspected outbreak or invasive GAS cluster",
        "Enhanced surveillance in affected settings (schools, military, healthcare facilities)",
        "Contact tracing for invasive GAS cases",
        "Public health education on symptoms and prevention",
        "Coordinate with schools and institutions for outbreak control",
        "Update stakeholders and healthcare providers"
      ],
      "prevention": [
        "Early diagnosis and treatment of pharyngitis (prevents acute rheumatic fever)",
        "Respiratory hygiene and cough etiquette",
        "Hand hygiene",
        "Exclude symptomatic individuals from close-contact settings until 24 hours after starting antibiotics",
        "Prompt treatment of skin infections",
        "Influenza and varicella vaccination (reduces risk of invasive GAS)",
        "No vaccine currently available for GAS",
        "Chemoprophylaxis for close contacts of invasive GAS cases (controversial, case-by-case basis)"
      ],
      "references": [
        {
          "label": "CDC - Group A Streptococcal (GAS) Disease",
          "url": "https://www.cdc.gov/groupastrep/index.html"
        },
        {
          "label": "WHO - Streptococcal Infections",
          "url": "https://www.who.int/health-topics/streptococcal-infections"
        },
        {
          "label": "Saudi GDIPC - Respiratory Infections",
          "url": "https://gdipc.org"
        }
      ]
    }
  ]
}

